Bluejay Diagnostics, Inc. BJDX
Bluejay Diagnostics, Inc. (Nasdaq: BJDX) is an infectious disease diagnostics company. Its next catalyst on record is Symphony IL-6 test: Complete analytical and clinical testing of SYMON-II samples (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Symphony IL-6 test — Complete analytical and clinical testing of SYMON-II samples (2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Symphony IL-6 test | Sepsis / septic shock mortality risk (SYMON-II pivotal study enrolling) | unclear | NA_NON_THERAPEUTIC |
| Symphony cardiac biomarker tests (hsTNT, NT-proBNP) | Myocardial infarction, congestive heart failure | unclear | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other infectious disease companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.